Cipla Informed Exchanges That The US FDA Conducted A Routine Current Good Manufacturing

Cipla informed exchanges that the US FDA conducted a routine current Good Manufacturing Practices audit at its Indore formulations facility during April 2-13.

"This was in the normal course of business. There were no data integrity and/or repeat observations. At this stage, the company believes the

observations are unlikely to have any material adverse impact," it said. The company will submit the response within the stipulated timeframe.

For more information ✆ +91 9111-179961 or Visit Dollar Advisory